In women with HER2-positive breast cancertreated with trastuzumab
It is known that up to 50% of patients with HER2-positive metastatic breast cancer:
Will develop brain metastasis
Any patient who has a persistent, worsening headache in the setting of prior HER2-positive breast cancer:
An MRI brain is warranted
References
1. Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast cancer patients at risk for Central Nervous System metastases in trials of the International Breast Cancer Study Group (IBCSG). Annals of oncology : official journal of the European Society for Medical Oncology. 2006;17(6):935-944.
2. Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, et al. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol. 2013;14(3):244-248.